QHSLab Valuation

Is USAQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of USAQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate USAQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate USAQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for USAQ?

Key metric: As USAQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for USAQ. This is calculated by dividing USAQ's market cap by their current revenue.
What is USAQ's PS Ratio?
PS Ratio	0.5x
Sales	US$1.82m
Market Cap	US$900.44k

USAQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	16.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does USAQ's PS Ratio compare to its peers?

The above table shows the PS ratio for USAQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.1x
SONX.D Sonendo	0.04x	2.8%	US$1.5m
ESMC Escalon Medical	0.09x	n/a	US$1.1m
LGMK LogicMark	0.4x	n/a	US$3.8m
DYNT Dynatronics	0.03x	n/a	US$943.9k
USAQ QHSLab	0.5x	n/a	US$900.4k

Price-To-Sales vs Peers: USAQ is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.1x).

Price to Sales Ratio vs Industry

How does USAQ's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.3x	8.2%
USAQ QHSLab	0.5x	n/a	US$900.44k
INGN Inogen	0.7x	4.2%	US$223.42m
ARAY Accuray	0.4x	5.5%	US$194.09m

50 Companies		Estimated Growth	Market Cap
Industry Avg.	3.3x	17.1%
USAQ QHSLab	0.5x	n/a	US$900.44k

No more companies

Price-To-Sales vs Industry: USAQ is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is USAQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

USAQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate USAQ's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

18.8%

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

0.5%

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

16.2%

99.5%